<SEC-DOCUMENT>0001193125-25-262971.txt : 20251104
<SEC-HEADER>0001193125-25-262971.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251103184811
ACCESSION NUMBER:		0001193125-25-262971
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251103
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251445753

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d65923d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as November 03, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#8217;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#8220;Yes&#8221; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d65923dex991.htm">Immutep Receives A$4.6 million R&amp;D Tax Incentive from French Government </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 03, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d65923dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65923dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">ASX/Media Release </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="center"><B>Immutep
Receives A$4.6&nbsp;million R&amp;D Tax Incentive from French Government </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="justify"><B>SYDNEY, AUSTRALIA &#8211; </B><B>3</B><B></B><B>&nbsp;November
2025 &#8211;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep&#8220; or &#8220;the Company&#8221;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, is pleased to announce it has received a <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>2,588,954 (~ A$4,567,769 ) research and development (R&amp;D) tax incentive payment in cash from the French Government under its Cr&eacute;dit d&#8217;Imp&ocirc;t Recherche scheme (CIR). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="justify">The &#8220;Cr&eacute;dit d&#8217;Imp&ocirc;t Recherche&#8221; (CIR), meaning &#8220;Research Tax Credit&#8221;, is a French government tax incentive
by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="justify">Immutep
qualifies for the CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France. The cash payment is provided in respect of expenditure incurred on eligible R&amp;D activities
conducted in the European Union in the 2024 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government&#8217;s R&amp;D tax incentive program in respect of expenditure incurred on eligible R&amp;D activities
conducted in Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="justify">The funds will be used to support the ongoing and planned global clinical development of eftilagimod alfa and IMP761.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="justify"><B>About Immutep</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="justify"><B></B>Immutep is a
late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation
<FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#8217;s</FONT> ability to stimulate or suppress the immune
response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit&nbsp;<U>www.immutep.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">Eleanor Pearson, Sodali&nbsp;&amp; Co </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">+61 (0)400 886 722; <U>eleanor.pearson@sodali.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri"><B>U.S. Investors/Media:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">Chris Basta, VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri">+1
(631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri" ALIGN="justify">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65923dsp4a.jpg" ALT="LOGO">
 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g65923dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65923dsp4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !E MH# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]/: "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /#?$7_(P:G_ -?4O_H9H ]RH * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H \-\1?\C!J?\ U]2_^AF@#W*@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M !!Z'- !0 4 % !0 4 >&^(O^1@U/_KZE_\ 0S0![E0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!X;XB_Y&#4_P#KZE_]#- 'N5 !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'AOB+_D8-3_ .OJ7_T,T >^_8/]O]* #[!_M_I0
M ?8/]O\ 2@ ^P?[?Z4 'V#_;_2@ ^P?[?Z4 'V#_ &_TH /L'^W^E !]@_V_
MTH /L'^W^E !]@_V_P!* #[!_M_I0 ?8/]O]* #[!_M_I0 ?8/\ ;_2@ ^P?
M[?Z4 'V#_;_2@ ^P?[?Z4 'V#_;_ $H /L'^W^E !]@_V_TH /L'^W^E !]@
M_P!O]* #[!_M_I0 ?8/]O]* #[!_M_I0 ?8/]O\ 2@ ^P?[?Z4 'V#_;_2@
M^P?[?Z4 'V#_ &_TH /L'^W^E !]@_V_TH /L'^W^E !]@_V_P!* #[!_M_I
M0 ?8/]O]* #[!_M_I0 ?8/\ ;_2@ ^P?[?Z4 'V#_;_2@ ^P?[?Z4 'V#_;_
M $H /L'^W^E !]@_V_TH /L'^W^E !]@_P!O]* #[!_M_I0 ?8/]O]* #[!_
MM_I0 ?8/]O\ 2@ ^P?[?Z4 'V#_;_2@ ^P?[?Z4 'V#_ &_TH /L'^W^E !]
M@_V_TH /L'^W^E !]@_V_P!* #[!_M_I0 ?8/]O]* #[!_M_I0 ?8/\ ;_2@
M ^P?[?Z4 'V#_;_2@ ^P?[?Z4 'V#_;_ $H /L'^W^E !]@_V_TH /L'^W^E
M !]@_P!O]* #[!_M_I0 ?8/]O]* #[!_M_I0 ?8/]O\ 2@ ^P?[?Z4 'V#_;
M_2@ ^P?[?Z4 'V#_ &_TH /L'^W^E !]@_V_TH /L'^W^E !]@_V_P!* #[!
M_M_I0 ?8/]O]* #[!_M_I0 ?8/\ ;_2@ ^P?[?Z4 'V#_;_2@ ^P?[?Z4 'V
8#_;_ $H \#\2KL\1ZJO7%W*/_'S0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g65923dsp4a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65923dsp4a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X K0# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ+^5 !]MD]%_*@ ^VR>B_E0 ?;9/1?RH /MLGHOY4 'VV3T7\J #[;)Z+^5
M!]MD]%_*@ ^VR>B_E0 ?;9/1?RH /MLGHOY4 'VV3T7\J #[;)Z+^5 !]MD]
M%_*@ ^VR>B_E0 ?;9/1?RH /MLGHOY4 'VV3T7\J #[;)Z+^5 !]MD]%_*@
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M)9<_7<WY5UT'NCX_/:+YH5EMM^IC?!/QO<?#RPU6_P!1LYW\.S[<31IDF<'
M5<D Y&<^F!5U(\[26YR99BI8.,IU$^1_F7OB1\<=)\>00:,-.N8M&:5))[EF
M"SC!ZHHR/7KG/MUJ84G'7J:XW-*6+2I<KY>KZ_(Y;X4:"FL?$^S;3Q+)I]E<
M?:EDF&&$:'*EL=R=H_&M*CM#4XLOHJKC(^S^%._R6Q]9?;9/1?RKSS]##[;)
MZ+^5 !]MD]%_*@ ^VR>B_E0 ?;9/1?RH /MLGHOY4 6;>4S(20 <XXH SJ "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MC_O4 4: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@"]9?ZH_P"]0!1H * "@ H * "@ H * "@
MH * "@ H * "@ H X/X]:>NK?!?QK9'3I=6FN-)N(K>S@M'NI)+@H1#MC56)
M(DV$$#Y2-V0!D:TG::9S8E<U&:M?3U]#Y\U_QC\4M OKG3O",7B/3O#UKIT:
M:=:P>$&:.%AIC2*BYML_\?*1QX/W?,;(X&WJ4:;UE:_KY^O8\N53$1?+3NE;
M3W?+T[Z":U\3OC1!J%]<62>)VMC<3F.R_P"$39@D:BS:(*_V;)W,]VASDA8S
MT.U@U"EUM]_KYA*MBDVU?_P'T\O4N^+?$?Q5U23QEHYG\5&QA=A;R1>'L&6
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MCXMO]13PVNC)J&L3ZAH\L6'\B9KA-D-D?+:.18PH>6,LH("R%U(F4(.ZCO\
MUYE0JUH.,JC=K7=UY.^RZ>J^9W?Q&ATR\\>>$&CTC4F\0+,DT&MPZ3=316<0
MWCRFF1"L7FEBC@D?)DO@*F<X747KH=57E=2.COWL]/\ *_7\3Q^+PAX]?P!=
M)IVFS:B)M4M-0U-]6BDT_4KB[W0L\1\NW)N((Y"_SGC"C:SHFVM^:'-K_P
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M_$2TEU2"RG\1R/!]H:%Y_#4VV11=DP!6CL7R[0,@(VXPI&8VW.+4(:7M]_\
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BE_N_J* #[++_ '?U% !]EE_N_J* +5K&T<9##!SF@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
